Page 82 - Immunization Practices News Today

RSV is one of the leading causes of infant hospitalization and the new antibody treatment could help to reduce these numbers.

Study findings show that most participants were aware of the human papillomavirus (HPV) vaccine, but had limited knowledge about the infection and the need to complete the whole series of shots.

Hosts review the July 13 WA State Vaccine Advisory Committee Meeting, including the concerns of Dr. Edgar Marcuse regarding the co-administration of flu, RSV, a

/PRNewswire/ -- The National Foundation for Infectious Diseases (NFID) has announced the appointment of Robert H. Hopkins, Jr., MD, as its new medical director....

The Food and Drug Administration (FDA) approved a drug to help protect infants from respiratory syncytial virus (RSV). The medication, given as a single-dose injection prior to or during RSV

A pharmacist dilutes the Pfizer COVID-19 vaccine as he prepares it for administration to staff and residents at Goodwin House Bailey's Crossroads, a senior

With the end of the national public health emergency for COVID-19 in May 2023, what can be expected as we look ahead to the 2023-2024 influenza season and beyond?

Sanofi's RSV antibody shot, nirsevimab, got FDA approval to protect infants on Monday.

The aims of the symposium were to describe the burden of infectious diseases in the adult population, including individuals with...

Respiratory syncytial virus is the leading cause of hospitalization in American infants.